{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/oscr-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/oscr-stock-analysis/data.json",
 "title": "Oscar Health (OSCR) Stock Forecast & Price Target (2026)",
 "description": "Oscar Health, Inc. (OSCR) stock: Healthcare, Healthcare Plans. $10.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Oscar Health, Inc. (OSCR)",
 "published": "2026-07-20T09:35:14+00:00",
 "modified": "2026-09-16T03:56:47.1+00:00",
 "generated": "2026-09-16T12:50:52.429Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "OSCR",
  "name": "Oscar Health, Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Healthcare Plans",
  "country": "United States",
  "website": "https://www.hioscar.com"
 },
 "quote": {
  "price": 32.44,
  "previousClose": 33.81,
  "change": -1.37,
  "changePercent": -4.05,
  "open": 33.5,
  "high": 33.72,
  "low": 32.3,
  "volume": 4265100,
  "averageVolume": 4865240,
  "marketCap": 10012443800,
  "fiftyTwoWeekHigh": 34.48,
  "fiftyTwoWeekLow": 10.69,
  "marketOpen": false,
  "asOf": "2026-09-16T03:56:47.000Z"
 },
 "statistics": {
  "pe": 24.953846,
  "eps": 1.3,
  "dividendYield": 0,
  "beta": 2.369,
  "priceToSales": 0.653612,
  "priceToBook": 4.8730655,
  "revenueTtm": 15318633472,
  "grossMargin": null,
  "returnOnEquity": 0.34257
 },
 "technicals": {
  "rsi": 57.25,
  "macd": 0.71,
  "sma50": 30.67,
  "sma200": 21.03,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 32.44,
  "analystTarget": 29,
  "analystCount": 11,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-16T03:56:47.000Z",
  "priceAtAnalysis": 32.44,
  "volatility": {
   "daily": 3.78,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 32.12,
  "aggressiveEntry": 32.44,
  "stopLoss": 29.87,
  "stopLossPercent": 7,
  "targets": [
   33.08,
   33.72,
   34.68
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 17.51,
    "base": 33.23,
    "upside90th": 63.07
   },
   {
    "year": 2028,
    "downside10th": 13.75,
    "base": 34.04,
    "upside90th": 84.24
   },
   {
    "year": 2029,
    "downside10th": 11.49,
    "base": 34.86,
    "upside90th": 105.77
   },
   {
    "year": 2030,
    "downside10th": 9.91,
    "base": 35.71,
    "upside90th": 128.64
   },
   {
    "year": 2031,
    "downside10th": 8.73,
    "base": 36.58,
    "upside90th": 153.28
   },
   {
    "year": 2032,
    "downside10th": 7.8,
    "base": 37.47,
    "upside90th": 180.02
   },
   {
    "year": 2033,
    "downside10th": 7.04,
    "base": 38.38,
    "upside90th": 209.1
   },
   {
    "year": 2034,
    "downside10th": 6.42,
    "base": 39.31,
    "upside90th": 240.78
   },
   {
    "year": 2035,
    "downside10th": 5.89,
    "base": 40.26,
    "upside90th": 275.29
   },
   {
    "year": 2036,
    "downside10th": 5.44,
    "base": 41.24,
    "upside90th": 312.88
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "OSCR Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$33.50",
    "Day Range": "$32.30 to $33.72",
    "Prev Close": "$33.81",
    "Volume": "4.27M",
    "52-Week Range": "$10.69 to $34.48",
    "Market Cap": "$10.01B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-22%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "OSCR Financial Performance",
   "text": [
    "Analysis: In the last 3 quarters, OSCR beat estimates 1 times. The stock rose 1 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "OSCR Analysis",
   "text": [
    "Oscar Health (OSCR) is currently trading above its 50-day Simple Moving Average (SMA) of $30.67 and its 200-day SMA of $21.03, indicating a generally positive short-to-medium term trend. The Relative Strength Index (RSI) is at 57.25, which is in neutral territory, suggesting neither overbought nor oversold conditions. The Moving Average Convergence Divergence (MACD) is positive at 0.71, further supporting the current upward momentum. The nearest support level is the 50-day SMA at approximately $30.67, while resistance can be observed near the current price. Volume has been slightly below its average, down 12.3%, which could indicate a lack of strong conviction behind recent price movements. The overall chart structure suggests a consolidation phase after recent gains, with key moving averages acting as support.",
    "Insiders have sold $156.9 million worth of shares against $11.9 million in purchases, signaling a strong bearish sentiment from management and potentially weighing on future stock performance.",
    "With 7 out of 11 analysts rating Oscar Health as 'Hold' and a median price target of $29.00, the market sentiment is divided, suggesting limited conviction for significant near-term upside.",
    "Oscar Health has reported impressive revenue growth of 70.4% and significant positive EPS surprises in recent quarters, indicating strong operational performance and market demand for its services.",
    "The stock is trading above its 50-day and 200-day moving averages ($30.67 and $21.03), with a neutral RSI and positive MACD, suggesting underlying technical strength and potential for continued upward movement.",
    "Oscar Health (OSCR) is expected to maintain its current trading range in the near term, with a base case projection of $35.71 by 2030. The company's strong revenue growth of 70.4% and positive recent earnings surprises provide a foundation for potential appreciation. However, the significant insider selling and a median analyst price target of $29.00 suggest that substantial upside may be limited. Key catalysts for future performance will likely revolve around continued execution in the competitive health insurance market and the ability to translate revenue growth into sustained profitability. A shift in insider sentiment from net selling to net buying, or a significant upgrade in analyst ratings, could provide a bullish catalyst. Conversely, any slowdown in revenue growth, increased regulatory scrutiny, or persistent insider selling could pressure the stock lower, potentially testing the downside projection of $9.91."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transactions closely; the current heavy selling trend warrants caution.",
     "The stock is trading above its 50-day and 200-day moving averages ($30.67 and $21.03), indicating positive short-term momentum, but watch for potential pullbacks to support levels around $30.67.",
     "Given the mixed analyst sentiment and insider selling, consider a more conservative position sizing until a clearer bullish trend emerges."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold $156.9 million worth of shares against $11.9 million in purchases, signaling a strong bearish sentiment from management and potentially weighing on future stock performance.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Neutral",
     "title": "Mixed Wall Street Analyst Ratings",
     "text": "With 7 out of 11 analysts rating Oscar Health as 'Hold' and a median price target of $29.00, the market sentiment is divided, suggesting limited conviction for significant near-term upside.",
     "source": "Analyst Ratings"
    },
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth and Earnings Beats",
     "text": "Oscar Health has reported impressive revenue growth of 70.4% and significant positive EPS surprises in recent quarters, indicating strong operational performance and market demand for its services.",
     "source": "Company Financials"
    },
    {
     "type": "Bullish",
     "title": "Positive Technical Momentum",
     "text": "The stock is trading above its 50-day and 200-day moving averages ($30.67 and $21.03), with a neutral RSI and positive MACD, suggesting underlying technical strength and potential for continued upward movement.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Oscar Health (OSCR) presents a mixed fundamental picture, trading at a price-to-sales ratio of 0.65, which is significantly below the sector median of 3.7, suggesting potential undervaluation on a sales basis. The company boasts a strong return on equity of 34.26% and a profit margin of 3.60%, indicating efficient operations and profitability. Its debt-to-equity ratio of 0.23 is well within a healthy range and below the sector average. However, the company's earnings per share (EPS) has been volatile, with recent quarters showing significant positive surprises, such as a 189.47% beat in the quarter to June 2026. Despite this, the current P/E ratio of 24.95 is relatively high given the mixed analyst sentiment and the median price target suggesting a slight downside. The substantial revenue growth of 70.4% is a key positive, but it needs to be weighed against the significant insider selling activity.",
    "Oscar Health (OSCR) has demonstrated strong earnings performance in recent quarters, notably beating EPS estimates by 189.47% in the quarter to June 2026, leading to a 5.12% price increase. The quarter to March 2026 also saw a substantial EPS beat of 88.18%, with a similar 5.19% stock price jump. While the quarter to December 2025 showed a negative surprise of -34.78% and a price drop, the overall trend in the most recent periods indicates a positive earnings trajectory and market reaction.",
    "A primary risk for Oscar Health (OSCR) is the significant insider selling, with over $156 million in sales against $11.9 million in purchases, indicating a 'heavy sell signal' from management. This heavy selling pressure could weigh on the stock price despite positive operational metrics. Also, the median analyst price target of $29.00 suggests a potential downside of 10.6% from the current trading price, indicating that Wall Street's outlook is not overwhelmingly bullish. The company's substantial revenue growth, while positive, also implies a need for continued strong execution to justify its current valuation."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "10.01B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "24.95"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "1.30"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "34.48"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "10.69"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($30.67) above the 200-day SMA ($21.03), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "57.25"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.71"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "30.67"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "21.03"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.23",
    "Correlation with Nasdaq 100 (QQQ)": "+0.20",
    "Correlation with Bitcoin (BTC)": "+0.24",
    "Correlation with Gold (XAU)": "+0.02"
   }
  },
  {
   "id": "trade-plans",
   "title": "OSCR Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (57.3) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$33.08",
    "TARGET 2": "$33.72",
    "TARGET 3": "$34.68",
    "STOP LOSS": "$29.87"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+18.89%",
    "Average Feb return": "+11.28%",
    "Average Mar return": "+0.26%",
    "Average Apr return": "+5.98%",
    "Average May return": "+3.80%",
    "Average Jun return": "+6.79%",
    "Average Jul return": "-5.23%",
    "Average Aug return": "+5.49%",
    "Average Sep return": "+2.09%",
    "Average Oct return": "-11.60%",
    "Average Nov return": "-0.05%",
    "Average Dec return": "-11.23%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "3.78%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in OSCR in March 2021 would be worth about $9,322 today, compared with about $19,857 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in OSCR today could grow to about $12,713 by 2036 in the base case, with a bull case near $96,449 and a bear case around $1,676. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "OSCR Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $35.71 for OSCR by 2030 in the base case, from $32.44 today (1.1x over 4 years). The downside path ends near $9.91. These are outcomes of a Monte Carlo simulation run on OSCR's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using OSCR's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "OSCR simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$17.51",
        "$33.23",
        "$63.07"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$13.75",
        "$34.04",
        "$84.24"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$11.49",
        "$34.86",
        "$106"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$9.91",
        "$35.71",
        "$129"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$8.73",
        "$36.58",
        "$153"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$7.80",
        "$37.47",
        "$180"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$7.04",
        "$38.38",
        "$209"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$6.42",
        "$39.31",
        "$241"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$5.89",
        "$40.26",
        "$275"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$5.44",
        "$41.24",
        "$313"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "CNC Centene Corp. NYSE $67.66 -2.52%",
     "url": "https://clearank.com/stock/centene-cnc/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $206.99 -3.31%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "HUM Humana Inc. NYSE $396.62 -2.56%",
     "url": "https://clearank.com/stock/hum-stock-analysis/"
    },
    {
     "text": "VRTX Vertex Pharmaceuticals Incorporated NASDAQ $514.63 -0.94%",
     "url": "https://clearank.com/stock/vertex-vrtx/"
    },
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $3.99 -3.62%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    },
    {
     "text": "JNJ Johnson & Johnson NYSE $266.93 +0.23%",
     "url": "https://clearank.com/stock/johnson-johnson-jnj/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $209.36 +3.01%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    },
    {
     "text": "QDEL QuidelOrtho Corporation NASDAQ $11.12 -5.60%",
     "url": "https://clearank.com/stock/quidelortho-qdel/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "OKLO vs SMR Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/oklo-vs-smr/"
    },
    {
     "text": "MPC vs PSX Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/mpc-vs-psx/"
    },
    {
     "text": "DOGE/USD vs SHIB/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/doge-vs-shib/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "OSCR Insider Trading Analysis",
   "facts": {
    "Bought": "$11.9M",
    "Sold": "$156.9M",
    "Insiders": "13",
    "Avg Transaction": "$4.7M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in OSCR",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Aug 17, 2023",
       "cells": [
        "ALPHABET, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "6.5M",
        "$52.5M"
       ]
      },
      {
       "label": "Jun 30, 2026",
       "cells": [
        "BERTOLINI MARK T Chief Executive Officer",
        "Sell",
        "1.2M",
        "$35.8M"
       ]
      },
      {
       "label": "Jun 26, 2026",
       "cells": [
        "BERTOLINI MARK T Chief Executive Officer",
        "Sell",
        "1.2M",
        "$34.9M"
       ]
      },
      {
       "label": "Jun 23, 2026",
       "cells": [
        "SCHLOSSER MARIO T Director",
        "Sell",
        "1.0M",
        "$30.2M"
       ]
      },
      {
       "label": "Aug 28, 2026",
       "cells": [
        "SCHLOSSER MARIO T Director",
        "Sell",
        "750.0K",
        "$22.8M"
       ]
      },
      {
       "label": "Mar 5, 2021",
       "cells": [
        "SCHLOSSER MARIO Chief Executive Officer",
        "Sell",
        "366.3K",
        "$11.4M"
       ]
      },
      {
       "label": "Sep 22, 2025",
       "cells": [
        "SCHLOSSER MARIO T Chief Technology Officer",
        "Sell",
        "395.0K",
        "$7.3M"
       ]
      },
      {
       "label": "Nov 12, 2025",
       "cells": [
        "SCHLOSSER MARIO T Chief Technology Officer",
        "Sell",
        "391.5K",
        "$6.0M"
       ]
      },
      {
       "label": "Jan 5, 2026",
       "cells": [
        "SCHLOSSER MARIO T Chief Technology Officer",
        "Sell",
        "234.9K",
        "$3.6M"
       ]
      },
      {
       "label": "Mar 5, 2021",
       "cells": [
        "JOYCE MEGHAN V Chief Operating Officer",
        "Sell",
        "95.4K",
        "$3.0M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Oscar+Health%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Oscar Health (OSCR) stock a buy right now?",
   "answer": "Oscar Health (OSCR) is currently trading at $32.44, which is its fair value. With a 'Hold' consensus rating and a median analyst price target of $29.00 suggesting a slight downside, it is not currently recommended as a strong buy."
  },
  {
   "question": "What is the outlook for Oscar Health (OSCR) stock?",
   "answer": "The outlook for Oscar Health (OSCR) is mixed. While the company shows strong revenue growth and recent positive earnings surprises, significant insider selling and a 'Hold' consensus from Wall Street temper the bullish sentiment. The stock is trading above key moving averages, suggesting short-term support, but the median analyst target implies limited upside."
  },
  {
   "question": "What are the biggest risks facing Oscar Health (OSCR)?",
   "answer": "The most significant risks for Oscar Health (OSCR) include heavy insider selling totaling over $156 million, which signals a lack of confidence from management. Additionally, the median analyst price target suggests a potential downside, and the company's valuation needs to be sustained by continued strong execution in a competitive healthcare market."
  },
  {
   "question": "How does Oscar Health (OSCR) compare to its sector peers?",
   "answer": "Oscar Health (OSCR) exhibits a price-to-sales ratio of 0.65, which is considerably lower than the sector median of 3.7, suggesting it is cheaper on a sales basis. However, its P/E ratio of 24.95 is higher than the sector median P/E of 31.9, indicating a premium valuation relative to its earnings. The company's revenue growth of 70.4% significantly outpaces the sector average of 8.1%."
  },
  {
   "question": "What is the consensus rating for Oscar Health (OSCR)?",
   "answer": "The consensus rating for Oscar Health (OSCR) is 'Hold', with a consensus score of 59 out of 100. This reflects a balanced view among analysts, with 7 out of 11 holding a 'Hold' rating."
  },
  {
   "question": "What are the recent earnings trends for Oscar Health (OSCR)?",
   "answer": "Oscar Health (OSCR) has shown strong positive earnings surprises in its most recent reported quarters, including a 189.47% EPS beat in the quarter to June 2026. This trend suggests improving operational efficiency and profitability, which has been met with positive stock price reactions."
  },
  {
   "question": "What is the long-term projection for Oscar Health (OSCR) stock?",
   "answer": "Based on Monte Carlo simulations, Oscar Health (OSCR) has a base case projection of $35.71 by 2030, with a downside scenario of $9.91 and an upside scenario of $128.64. These are statistical outcomes, not price targets, and should be viewed with caution."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "CNC",
    "name": "Centene Corp. NYSE",
    "price": "$67.66",
    "change": "-2.52%",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$206.99",
    "change": "-3.31%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "HUM",
    "name": "Humana Inc. NYSE",
    "price": "$396.62",
    "change": "-2.56%",
    "url": "https://clearank.com/stock/hum-stock-analysis/"
   },
   {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Incorporated NASDAQ",
    "price": "$514.63",
    "change": "-0.94%",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   },
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$3.99",
    "change": "-3.62%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "JNJ",
    "name": "Johnson & Johnson NYSE",
    "price": "$266.93",
    "change": "+0.23%",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$209.36",
    "change": "+3.01%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "QDEL",
    "name": "QuidelOrtho Corporation NASDAQ",
    "price": "$11.12",
    "change": "-5.60%",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   }
  ],
  "comparisons": [
   {
    "ticker": "OKLO vs SMR Comparison",
    "name": "",
    "url": "https://clearank.com/compare/oklo-vs-smr/"
   },
   {
    "ticker": "MPC vs PSX Comparison",
    "name": "",
    "url": "https://clearank.com/compare/mpc-vs-psx/"
   },
   {
    "ticker": "DOGE/USD vs SHIB/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/doge-vs-shib/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "COIN",
    "text": "↓ 10.10%",
    "url": "https://clearank.com/stock/coinbase-coin/"
   },
   {
    "ticker": "AXON",
    "text": "↓ 9.98%",
    "url": "https://clearank.com/stock/axon-enterprise-axon/"
   },
   {
    "ticker": "XLM/USD",
    "text": "↓ 9.86%",
    "url": "https://clearank.com/crypto/stellar-xlm-usd/"
   },
   {
    "ticker": "AERO/USD",
    "text": "↓ 9.65%",
    "url": "https://clearank.com/crypto/aero-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "CVS",
    "text": "CVS Health",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   },
   {
    "ticker": "ELV",
    "text": "Elevance Health",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   },
   {
    "ticker": "HUM",
    "text": "Humana Inc",
    "url": "https://clearank.com/stock/hum-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "text": "Molina Healthcare Inc.",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "UNH",
    "text": "UnitedHealth Group",
    "url": "https://clearank.com/stock/unitedhealth-group-unh/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/oscr-oscar-health-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/oscr-oscar-health-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Oscar Health (OSCR) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/oscr-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/oscr-stock-analysis/",
        "name": "Oscar Health (OSCR) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/oscr-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/oscr-stock-analysis/",
     "name": "Oscar Health (OSCR) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-20T09:35:14+00:00",
     "dateModified": "2026-09-16T03:56:47+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/oscr-oscar-health-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/oscr-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/oscr-stock-analysis/#richSnippet",
     "headline": "Oscar Health (OSCR) Stock Forecast & Price Target (2026)",
     "name": "Oscar Health (OSCR) Stock Forecast & Price Target (2026)",
     "description": "Oscar Health, Inc. (OSCR) stock: Healthcare, Healthcare Plans. $10.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-20T09:35:14+00:00",
     "dateModified": "2026-09-16T03:56:47+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Oscar Health, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "OSCR"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States. Oscar Health combines insurance coverage with a technology platform designed to help members access car",
      "tickerSymbol": "OSCR",
      "sameAs": "https://www.hioscar.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/oscr-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/oscr-oscar-health-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/oscr-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Oscar Health (OSCR) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Oscar Health (OSCR) is currently trading at $32.44, which is its fair value. With a 'Hold' consensus rating and a median analyst price target of $29.00 suggesting a slight downside, it is not currently recommended as a strong buy."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for Oscar Health (OSCR) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The outlook for Oscar Health (OSCR) is mixed. While the company shows strong revenue growth and recent positive earnings surprises, significant insider selling and a 'Hold' consensus from Wall Street temper the bullish sentiment. The stock is trading above key moving averages, suggesting short-term support, but the median analyst target implies limited upside."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks facing Oscar Health (OSCR)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The most significant risks for Oscar Health (OSCR) include heavy insider selling totaling over $156 million, which signals a lack of confidence from management. Additionally, the median analyst price target suggests a potential downside, and the company's valuation needs to be sustained by continued strong execution in a competitive healthcare market."
     }
    },
    {
     "@type": "Question",
     "name": "How does Oscar Health (OSCR) compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Oscar Health (OSCR) exhibits a price-to-sales ratio of 0.65, which is considerably lower than the sector median of 3.7, suggesting it is cheaper on a sales basis. However, its P/E ratio of 24.95 is higher than the sector median P/E of 31.9, indicating a premium valuation relative to its earnings. The company's revenue growth of 70.4% significantly outpaces the sector average of 8.1%."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus rating for Oscar Health (OSCR)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus rating for Oscar Health (OSCR) is 'Hold', with a consensus score of 59 out of 100. This reflects a balanced view among analysts, with 7 out of 11 holding a 'Hold' rating."
     }
    },
    {
     "@type": "Question",
     "name": "What are the recent earnings trends for Oscar Health (OSCR)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Oscar Health (OSCR) has shown strong positive earnings surprises in its most recent reported quarters, including a 189.47% EPS beat in the quarter to June 2026. This trend suggests improving operational efficiency and profitability, which has been met with positive stock price reactions."
     }
    },
    {
     "@type": "Question",
     "name": "What is the long-term projection for Oscar Health (OSCR) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Oscar Health (OSCR) has a base case projection of $35.71 by 2030, with a downside scenario of $9.91 and an upside scenario of $128.64. These are statistical outcomes, not price targets, and should be viewed with caution."
     }
    }
   ]
  }
 ]
}